Raymond James Lowers Earnings Estimates for Medexus Pharmaceuticals (TSE:MDP)

Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) has faced a reduction in earnings estimates from research analysts at Raymond James. In a report published on February 6th, they announced that the Q4 2026 earnings per share (EPS) estimates for Medexus Pharmaceuticals have been decreased. Analyst M. Freeman revised their outlook, now predicting that the company will achieve earnings of $0.06 per share for that quarter, down from a previous estimate of $0.07.

Raymond James continues to maintain a "Strong-Buy" rating on Medexus Pharmaceuticals, setting a price target of $4.00 for the stock. For the company's current fiscal year, the consensus estimate for earnings stands at $0.16 per share. Additionally, Raymond James has projected future earnings, estimating EPS of $2.16 for FY2028 and $3.07 for FY2029.

Other analysts have also weighed in on Medexus Pharmaceuticals. Stifel Nicolaus recently downgraded the company from a "buy" rating to a "hold" rating, lowering their price target from C$6.00 to C$3.45. Meanwhile, Ventum Capital Markets upgraded the stock to a "strong-buy" rating as of January 17th, and on January 30th, they raised their price target from C$5.00 to C$6.25. Stifel Canada has also shifted their rating from "strong-buy" to "hold." Notably, Alliance Global Partners upgraded Medexus Pharmaceuticals to a "strong-buy" on December 23rd. Overall, two analysts hold a "hold" rating, one has a buy rating, and four analysts have classified the stock as a strong buy. MarketBeat.com data reveals that the average rating for the stock is "Buy" with a consensus target price of C$5.49.

Current Price Performance of Medexus Pharmaceuticals

As of Monday, shares of TSE:MDP opened at C$3.21. The company's 50-day simple moving average is C$3.54, while the 200-day simple moving average stands at C$2.83. With a market capitalization of C$78.74 million and a price-to-earnings ratio of 64.20, Medexus Pharmaceuticals shows a beta of 1.96. The stock has experienced a 12-month low of C$1.47 and a high of C$5.56.

Company Overview of Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in both Canada and the United States. The firm focuses on various therapeutic areas, including oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. Its key products consist of IXINITY, a treatment for hemophilia B; Rasuvo and Metoject, which are formulated for rheumatoid arthritis; Rupall, an allergy medication; and Gleolan, an optical imaging agent for surgeries involving glioma.

Earnings, Estimates, Pharmaceuticals